• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 15th July 2013

OHE Involved in Developing New AMS Report on Stratified Medicines

Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential of Stratified Medicine, a new report by the UK’s Academy of Medical Sciences. Adrian…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential of Stratified Medicine, a new report by the UK’s Academy of Medical Sciences. Adrian and Professor Lou Garrison, OHE Visiting Senior Research Fellow, were two of a dozen experts who oversaw the preparation of the report.

Prof Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential of Stratified Medicine, a new report by the UK’s Academy of Medical Sciences. Adrian and Prof Lou Garrison, OHE Visiting Senior Research Fellow, were two of a dozen experts who oversaw the preparation of the report. Towse and Garrison chaired the two working groups examining pricing and reimbursement issues.

Stratified medicine, according to the report, “is the grouping of patients based on risk of disease or response to therapy by using diagnostic tests or techniques”. Its benefit for patients and health care providers is more targeted and effective treatments. The biopharmaceutical industry benefits from both a potentially more efficient development process as well as markets for these new treatments.

The importance of stratified medicine is clear from the case studies included in the report. For example, it can identify the 2–9% of patients who have a genetic biomarker for hypersensitivity to Ziagen® (abacavir), an HIV medication, thereby avoiding severe reactions. Similarly, Xalkori® (crizotinib) is markedly more effective than alternative treatments for a subset of patients with a particular strain of lung cancer, identified by genetic testing.

The report finds, however, that existing regulatory and pricing systems are not designed to enable the effective, widespread adoption of a stratified, and increasingly personalised, approach to medicine—and instead are imposing serious barriers. Under current pricing systems, for example, the price of a medicine remains the same or decreases after it reaches the market. Raising the price in response to the development of a new, targeted use is not possible, missing an important incentive for developing increasingly personalised medicines. Similarly, new incentives are essential for the development of the diagnostic tests that are the backbone of stratified and personalised medicine.

The pricing and reimbursement recommendations included in the report include the following.

  • Introducing flexible pricing for drugs and prices reflective of value for diagnostics. This is to address scenarios in which the drug and diagnostic are launched together, as co-dependent technologies, and when the potential for better targeting of the medicine only becomes clearer after marketing.
  • Developling approaches whereby health technology assessment of diagnostics can appropriately value platform technologies, such as human genome sequencing, that can test for a number of different ways of stratifying populations in different disease areas.
  • Apportioning value between the drug and the diagnostic appropriately. For economists the value is jointly created and any attribution is arbitrary. However, the way that drugs and diagnostics are priced to reflect this value can have significant implications for the rate of future innovation.
  • Recognising that evidence requirements for companion diagnostics need to be flexible to limit the complexities added to drug development.  More accurate tests are crucial to improving health, yet the resources available to diagnostic manufacturers to undertake independent clinical studies are limited. Coverage with evidence development may be one route forwards to earlier access to important diagnostics.
  • Exploring how diagnostic manufacturers can receive better intellectual property or data exclusivity protection to create incentives for generating better evidence of clinical value. One approach would be NHS use of diagnostic kits with an evidence base in preference to in-house tests with no such evidence base.

The report also emphasises the critical need to harmonise and link clinical databases and biobanks, nationally and worldwide, and to follow proposed “Good Genomic Practice” guidelines in collecting such data to maximise its research potential.

For the use of stratified and personalised medicines to become an everyday practice in health care, the report notes, a wide range of groups must become involved in implementing the report’s recommendations. This includes thought leaders in academia, policy makers in health care systems, the private sector, research funders, licensing authorities and regulators, health technology assessment bodies and patients’ groups. The report calls for the expansion of the UK Stratified Medicine Innovation Platform to provide the framework for bringing all stakeholders together, unifying existing initiatives and co-ordinating future activities.

Copies of the report are available for download from The Academy of Medical Sciences. OHE has been involved in exploring many of these issues recently including the following, for example.

  • Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10(1), 61-72. An earlier version is available as an OHE Research Paper.
  • Mattison, N. ed. (2013) The Challenges and Economics of Drug Development in 2022. London: Office of Health Economics.
  • Prof Towse’s analysis of valuing stratified/personalised medicine is contained in this short video: Challenges in valuing genomic medicines.
  • Drug Development/R&D
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
  • News
  • May 2020

Indication-Based Pricing: Are We All Onboard?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!